Enrique A Conterno
CIK 1476151 · Chief Executive Officer · last filed 2023-07-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LLY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
INDIANAPOLIS, IN 46285
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYNTRA BIO, INC. (FGEN) Delisted | Chief Executive Officer | 16,101 | $9.75 | $157.0K | -$828.9K | 22 | 2023-07-10 |
| LLY | SVP&Pres, LillyDiab & LillyUSA | 163,121 | $1273.46 | $207.73M | -$13.33M | 43 | 2019-02-20 |
Recent Filings · Page 3 of 7
65 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-12 | KYNTRA BIO, INC. (FGEN) Delisted | Buy (P) | +27,800 | $988.9K | EDGAR |
| 2020-01-08 | KYNTRA BIO, INC. (FGEN) Delisted | Grant (A) | +60,000 | $0 | EDGAR |
| 2019-02-20 | LLY | Grant (A) | +26,682 | $3.21M | EDGAR |
| 2019-02-20 | LLY | Sell (S) | −25,000 | -$3.02M | EDGAR |
| 2019-02-06 | LLY | Grant (A) | +26,681 | $3.21M | EDGAR |
| 2019-02-05 | LLY | Mixed | +6,746 | -$656.4K | EDGAR |
| 2018-06-01 | LLY | Sell (S) | −25,000 | -$2.12M | EDGAR |
| 2018-05-03 | LLY | Mixed | +11,066 | -$724.3K | EDGAR |
| 2018-02-05 | LLY | Mixed | +11,814 | -$774.8K | EDGAR |
| 2018-01-31 | LLY | Grant (A) | +12,437 | $1.09M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.